Global Life Sciences Software Market: Meeting Biopharma Demands with 11-12% CAGR Growth by 2029

The global Life Sciences Software market is expected to grow at a CAGR of 11-12% by 2029, driven by increasing R&D activities across the world, stringent regulatory compliance/reporting, rising use of AI & ML in drug discovery and clinical trial phases, and growing demand for novel software solutions specifically designed for biologics/cell & gene therapy.

The life science industry is rapidly evolving and is increasingly looking for automation and digital data management technologies to research and innovate most efficiently and accurately possible. The market for life sciences software (such as eTMF, LIMS, computer-aided drug discovery, RWE, ERP, CRM, QMS, virtual trials, patient recruitment software, patient & outcomes data management, etc.) is driven by the increasing R&D spending and pipeline, growing number and size of biotechs, Covid-accelerated decentralized trials, increasing cost efficiencies and shorter time to market.

🔗 Want deeper insights? Download the sample report:
https://meditechinsights.com/life-sciences-software-market/request-sample/

Mounting Interest in Novel Software Solutions Specifically Designed for Biologics

Advanced therapies, such as cell and gene therapies and personalized vaccines require advanced software infrastructure across the entire development and manufacturing process. With rapidly expanding research on cell and gene therapies and a healthy CGT pipeline, there is robust demand for software solutions to maximize process and workflow efficiencies across services. Some of the key technology providers for CGT include Vineti, TrakCel, Be The Match, SAP, WellSky, Synthace and Cytiva. The FDA predicts that by 2025, 10 to 20 cell and gene therapy products will be approved a year. Companies are entering/expanding into the Biologics software space to leverage growth opportunities. For instance,

• In Oct 2021, Körber, the leading supplier of manufacturing IT solutions for pharma and biotech, and Vineti, the leading digital enterprise platform provider for cell and gene therapy supply chains and data management, entered into a partnership to provide improved manufacturing performance and global visibility for CGT

COVID-19 Impact on Life Sciences Software Market

Covid-19 has impacted all phases of drug development however, the clinical trials phase was hit the most. This paved the way for technological solutions to overcome such hurdles. Virtual trials have become more important than ever post-pandemic. There were hardly any M&As related to virtual trials taking place before the pandemic, but the market observed ~10 M&A deals in 2020. The companies are increasingly consolidating through M&As to enhance their technology/service offerings for decentralized trials and leverage growth opportunities in the life sciences software market.

Regional Trends: Medical image analysis software market

The life sciences software market, encompassing biotechnology, pharmaceuticals, biomedical technologies, and healthcare, supports R&D, clinical trials, regulatory compliance, and data management. North America leads this market due to its advanced healthcare infrastructure, significant R&D investments, and the presence of key players like Oracle and IBM, with trends showing increased adoption of AI and big data analytics. Europe, the second-largest market, benefits from a robust healthcare system, substantial government R&D funding and a focus on personalized medicine and GDPR compliance. The Asia-Pacific region, experiencing the fastest growth, is driven by rising healthcare investments, clinical trial activities, and expanding pharmaceutical markets in China, India, and Japan, with local and international companies like Infosys and Wipro contributing to this growth amid rapid digital transformation and government initiatives.

Drug Discovery Software Likely to Witness Fastest Growth

The life sciences software market value chain segment, includes Drug Discovery, Drug Development/Clinical Trial Management Systems (CTMS), Drug Manufacturing, and Commercialization, each with distinct market shares and growth dynamics. The drug discovery software market, though niche, is rapidly expanding due to the increasing pressure on pharmaceutical and biotech companies to reduce costs and timelines in the research and preclinical stages. Advanced deep-learning software tools are instrumental in enhancing transparency and efficiency in this segment. Drug development and CTMS software are crucial for managing and optimizing clinical trials, representing a significant portion of the market as companies seek to streamline trial processes and ensure regulatory compliance. Drug manufacturing software supports the production process by ensuring quality control and compliance with stringent regulations. Lastly, commercialization software aids in market analysis, customer relationship management, and strategic product launches.

“Large players present in this segment are trying to consolidate the market by becoming a one-stop shop. Moreover, companies are also considering to combine their solutions with bioinformatics and LIMS tools to have a competitive edge.” - Executive, Leading Drug Discovery Software Provider, US

Gain a competitive edge-request a sample report now! 
https://meditechinsights.com/life-sciences-software-market/request-sample/

Rising Demand for Cloud-based Software

The life science software market is segmented into On-Premise and On-Demand/Cloud delivery models, each with distinct market dynamics. On-premise systems, despite their historical prevalence, are increasingly challenged by the need for efficient data sharing and integration across organizations. These systems are often characterized by high implementation and management costs, and they lack the scalability and flexibility required in today’s data-driven environment. As a result, their market share is declining. In contrast, the On-Demand/Cloud segment is experiencing a surge in demand, capturing a significant portion of the market due to its advantages such as quick deployment, minimal upfront costs, and superior scalability. This model is particularly appealing to small and medium-sized pharmaceutical companies, biotech’s, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs), which benefit from its affordability and operational efficiency.

Competitive Landscape: Life Sciences Software Market

The global life sciences software market is highly competitive and fragmented. Some of the key players having a strong foothold in the global life science software market include Dassault Systèmes, LabVantage, PerkinElmer, Schrodinger, ICON, Veeva, PhlexGlobal, Saama Technologies, IQVIA, Parexel, Signant Health, Calyx, Salesforce, ConcertAI, Abbott, Science37, Healx, Medidata, IBM Watson Health, Koneksa, SAP, Oracle, Optibrium, Verily and Exploristics among others.

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
Associate, Medi-Tech Insights
 +32 498 86 80 79
 info@meditechinsights.com